• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Ismail, E., Elearyan, E., Tahoun, M., Agwa, A. (2024). EVALUATION OF SERUM LEVEL OF CXCL12 AND ITS RELATION TO DISEASE ACTIVITY IN VITILIGO PATIENTS. ALEXMED ePosters, 6(2), 44-45. doi: 10.21608/alexpo.2024.296695.1862
Eisha AbdElmoneim Ismail; Eman Moahmed Elearyan; Mona Moustafa Tahoun; Alaa Ramadan Mohamed Agwa. "EVALUATION OF SERUM LEVEL OF CXCL12 AND ITS RELATION TO DISEASE ACTIVITY IN VITILIGO PATIENTS". ALEXMED ePosters, 6, 2, 2024, 44-45. doi: 10.21608/alexpo.2024.296695.1862
Ismail, E., Elearyan, E., Tahoun, M., Agwa, A. (2024). 'EVALUATION OF SERUM LEVEL OF CXCL12 AND ITS RELATION TO DISEASE ACTIVITY IN VITILIGO PATIENTS', ALEXMED ePosters, 6(2), pp. 44-45. doi: 10.21608/alexpo.2024.296695.1862
Ismail, E., Elearyan, E., Tahoun, M., Agwa, A. EVALUATION OF SERUM LEVEL OF CXCL12 AND ITS RELATION TO DISEASE ACTIVITY IN VITILIGO PATIENTS. ALEXMED ePosters, 2024; 6(2): 44-45. doi: 10.21608/alexpo.2024.296695.1862

EVALUATION OF SERUM LEVEL OF CXCL12 AND ITS RELATION TO DISEASE ACTIVITY IN VITILIGO PATIENTS

Article 1, Volume 6, Issue 2, April 2024, Page 44-45  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2024.296695.1862
View on SCiNiTO View on SCiNiTO
Authors
Eisha AbdElmoneim Ismail1; Eman Moahmed Elearyan2; Mona Moustafa Tahoun3; Alaa Ramadan Mohamed Agwa email 4
1Dermatology, Venereology and Andrology, Faculty of Medicine, Alexandria University.
2Department of Dermatology, Venereology and Andrology , Faculty of Medicine, Alexandria University, Egypt.
3Department of Clinical and Chemical Pathology, Faculty of Medicine University of Alexandria.
4Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Alexandria University.
Abstract
Vitiligo is a pigmentary disorder with an unknown cause that affects the skin and is characterized by well-defined, depigmented macules and patches that develop as a result of the selective loss of melanocytes. Vitiligo can be classified into segmental and nonsegmental which is the most common and unclassifible vitiligo. The pathogenesis of vitiligo is still unclear but it may be due to interplay of theories including genetic, environmental factors, immunological theory, reactive oxygen system theory, and neural theory. Treatment for vitiligo aims to promote repigmentation and cause stability. There are three types of treatment: pharmaceutical, surgical, and physical.
CXCL12 is an effective vitiligo predictor. In early vitiligo, it is produced by epidermal melanocytes and is surrounded by CXCR4+ cells.CXCR4 and CXCL12 have been recognized as critical mediators for mobilizing the IFN-producing cells and Langerhans cellsto the site’s proximity to melanocytes, resulting in melanocyte destruction and pigmentation in the skin.

AIM:
The aim of this work was to evaluate serum level of C-X-C motif chemokine ligand 12 (CXCL12) and its relation to disease activity in vitiligo patients.
Keywords
CXCL12; vitiligo; activity
Supplementary Files
download 20 modifided 1.pdf
Statistics
Article View: 74
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.